Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ardelyx (ARDX) stocks in Canada

Learn how to easily invest in Ardelyx stocks.

Ardelyx is a biotechnology business based in the US. Ardelyx stocks (ARDX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.95 – a decrease of 6.8% over the previous week. Ardelyx employs 129 staff and has a trailing 12-month revenue of around $10.9 million.

How to buy shares in Ardelyx

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARDX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Ardelyx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Ardelyx's stock price?

Since the stock market crash in March caused by coronavirus, Ardelyx's stock price has had significant negative movement.

Its last market close was $0.932, which is 88.38% down on its pre-crash value of $8.02 and 352.79% down on the lowest point reached during the March crash when the stocks fell as low as $4.22.

If you had bought $1,000 worth of Ardelyx stocks at the start of February 2020, those stocks would have been worth $794.48 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $128.55.

Ardelyx stock price (NASDAQ:ARDX)

Use our graph to track the performance of ARDX stocks over time.

Ardelyx shares at a glance

Information last updated 2022-01-11.
Latest market close$0.93
52-week range$0.82 - $9.23
50-day moving average $1.17
200-day moving average $3.69
Wall St. target price$6.86
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.54

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Ardelyx price performance over time

Historical closes compared with the close of $0.932 from 2022-01-14

1 week (2022-01-07) -6.80%
1 month (2021-12-15) -22.33%
3 months (2021-10-12) N/A
6 months (2021-07-16) -87.57%
1 year (2021-01-15) -86.33%
2 years (2020-01-16) -87.00%
3 years (2019-01-16) 2.23
5 years (2017-01-13) 14.7

Ardelyx financials

Revenue TTM $10.9 million
Gross profit TTM $-57,627,000
Return on assets TTM -48.43%
Return on equity TTM -141.76%
Profit margin 0%
Book value $0.76
Market capitalisation $112.7 million

TTM: trailing 12 months

Ardelyx share dividends

We're not expecting Ardelyx to pay a dividend over the next 12 months.

Ardelyx share price volatility

Over the last 12 months, Ardelyx's shares have ranged in value from as little as $0.816 up to $9.23. A popular way to gauge a stock's volatility is its "beta".

ARDX.US volatility(beta: 1.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ardelyx's is 1.6959. This would suggest that Ardelyx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ardelyx overview

Ardelyx, Inc. , a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.

Stocks similar to Ardelyx

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site